Left ventricular hypertrophy offsets the sex difference in cardiovascular risk (the Campania Salute Network).

[1]  G. de Simone,et al.  Differential effect of obesity on prevalence of cardiac and carotid target organ damage in hypertension (the Campania Salute Network). , 2017, International journal of cardiology.

[2]  G. de Simone,et al.  Effect of diabetes and metabolic syndrome on myocardial mechano-energetic efficiency in hypertensive patients. The Campania Salute Network , 2017, Journal of Human Hypertension.

[3]  R. Devereux,et al.  Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study , 2017, Blood pressure.

[4]  G. de Simone,et al.  Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network) , 2017, Journal of the American Heart Association.

[5]  Ivar Heuch,et al.  Lifelong Gender Gap in Risk of Incident Myocardial Infarction: The Tromsø Study. , 2016, JAMA internal medicine.

[6]  Faisal Rahman,et al.  Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis , 2016, Nature Reviews Cardiology.

[7]  O. Holmen,et al.  Blood pressure changes during 22-year of follow-up in large general population - the HUNT Study, Norway , 2016, BMC Cardiovascular Disorders.

[8]  G. de Simone,et al.  Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network. , 2015, International journal of cardiology.

[9]  J. Gottdiener,et al.  Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)†. , 2015, European heart journal cardiovascular Imaging.

[10]  G. Aurigemma,et al.  Cardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalities , 2015, Journal of hypertension.

[11]  M. Woodward,et al.  Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events , 2014, Diabetologia.

[12]  Gustavo Saposnik,et al.  Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2014, Stroke.

[13]  T. Kitazono,et al.  Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease , 2014, Hypertension Research.

[14]  G. de Simone,et al.  Are Observational Studies More Informative Than Randomized Controlled Trials in Hypertension?: Pro Side of the Argument , 2013, HYPERTENSION.

[15]  G. de Simone,et al.  Hypertensive target organ damage predicts incident diabetes mellitus , 2013, European heart journal.

[16]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension , 2007, Blood pressure.

[17]  M. Nieminen,et al.  Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[18]  D. Levy,et al.  Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. , 2012, European heart journal.

[19]  B. Howard,et al.  Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study , 2011, Journal of hypertension.

[20]  C. Noel Bairey Merz,et al.  Women and ischemic heart disease: evolving knowledge. , 2009, Journal of the American College of Cardiology.

[21]  S. Oparil,et al.  Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study , 2008, Hypertension.

[22]  P. Okin,et al.  Gender Differences in Left Ventricular Structure and Function During Antihypertensive Treatment: The Losartan Intervention for Endpoint Reduction in Hypertension Study , 2008, Hypertension.

[23]  Raffaele Izzo,et al.  The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis , 2005, Journal of hypertension.

[24]  Seppo Lehto,et al.  Gender difference in the impact of type 2 diabetes on coronary heart disease risk. , 2004, Diabetes care.

[25]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[26]  S. Daskalopoulou,et al.  The impact of serum uric acid on cardiovascular outcomes in the LIFE study. , 2004, Kidney international.

[27]  Stuart R Lipsitz,et al.  Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. , 2003, Archives of internal medicine.

[28]  M. Nieminen,et al.  Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. , 2002, JAMA.

[29]  B. Howard,et al.  A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. , 2001, American heart journal.

[30]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[31]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[32]  C. Borghi,et al.  Serum uric acid and acute coronary syndrome: Is there a role for functional markers of residual cardiovascular risk? , 2018, International journal of cardiology.

[33]  K. Schenck-Gustafsson,et al.  Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. , 2016, European heart journal.